ERBB2 and breast neoplasm: Current therapeutic options for HER2+ breast tumors target the HER2 receptor using either monocolonal antibodies (e.g. trastuzumab, pertuzumab) or small molecule receptor tyrosine kinase inhibitors (e.g. lapatinib, neratinib).